Augmented Vs. Normal Renal Replacement Therapy in Severe Acute Renal Failure (ARF).

Summary

This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).

Conditions

• Acute Renal Failure

Interventions

PROCEDURE

"augmented" CRRT regimen

We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.

Sponsors & Collaborators

• ANZICS Clinical Trials Group

  collaborator NETWORK

• The George Institute

  lead OTHER

Principal Investigators

• Prof Rinaldo Bellomo, MD · Austin Hospital, Melbourne Australia

• Alan Cass, MD · The George Institute

• Simon Finfer, MD · Royal North Shore Hospital

• Carlos Scheinkestel, MD · The Alfred

• Robyn Norton, MD · The George Institute

• John Myburgh, MD · St George Hospital (Sydney)

• Louise Cole, MD · Nepean Blue Mountains Local Health District

• Martin Gallagher, MD · The George Institute

• Shay McGuinness, MD · Auckland City Hospital CVICU

• Colin McArthur, MD · Auckland City Hospital DCCM

Study Design

Allocation

RANDOMIZED

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-11-30

Primary Completion

2008-10-31

Completion

2009-01-31

Countries

• Australia

Study Locations